Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

Biosante and Cell Genesys to merge after stockholders' approval

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and Cell Genesys, Inc. (NASDAQ: CEGE), today announced that each will hold a special stockholders meeting on September 30, 2009 at which time stockholders will be asked to approve the previously announced merger between the companies. On June 29, 2009, BioSante and Cell Genesys entered into a definitive merger agreement by which the companies will merge in an all-stock transaction, with BioSante as the surviving company.

3 Sep 2009

Biosante Pharmaceuticals and Cell Genesys to hold stockholders meeting for merger approval

BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. (NASDAQ:CEGE), today announced that each will hold a special stockholders meeting on September 30, 2009 at which time stockholders will be asked to approve the previously announced merger between the companies.

3 Sep 2009

Phase I clinical trial data of GDC-0449 published in the New England Journal Of Medicine

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines for cancer treatment, today announced that two publications describing clinical data generated with GDC-0449 were published in the current edition of The New England Journal of Medicine (NEJM).

3 Sep 2009

Study reports a potential new investigational therapy for skin cancer

A study published today in the New England Journal of Medicine reports a potential new investigational therapy for advanced and metastatic basal cell skin cancer tested at the Virginia G. Piper Cancer Center at Scottsdale Healthcare and other sites appears to demonstrate tumor shrinkage and limited side effects in patients.

3 Sep 2009

New therapy for advanced and metastatic basal cell skin cancer

3 Sep 2009

Statistics reveals that blacks experience higher rates of pancreatic cancer deaths than whites

Regardless of risk factors linked to pancreatic cancer, such as smoking and body mass index (BMI), blacks experienced higher rates of pancreatic cancer death than whites.

2 Sep 2009

Leading experts in health and health care reform to take part in symposium

With the nation facing a $9 trillion deficit over the next 10 years, according to government estimates, the future of health care reform depends upon a neglected but critical leg of the equation: cost. Some of the nation’s leading experts in health and health care reform will provide insights into this issue when they converge in Nashville Saturday for a nonpartisan public discussion.

29 Aug 2009

Genvec to sell 8,000,000 shares to develop its TNFerade clinical program

GenVec, Inc. (Nasdaq: GNVC) announced today that it has entered into a purchase agreement with a single institutional investor for the sale of 8,000,000 shares of its common stock and warrants to purchase 4,000,000 shares of its common stock. The shares of common stock and warrants are being offered in units consisting of one share of common stock and 0.50 warrants to purchase one share of common stock at a price of $0.75 per unit. This represents a discount of approximately 8.3% to the closing price of GenVec common stock on August 26, 2009. The warrants have a term of five years and an exercise price of $0.828 per share.

28 Aug 2009

Tikcro Technologies announces financial results for the second-quarter ended June 30, 2009

Tikcro Technologies Ltd. (OTC BB: TIKRF) today reported results for the second quarter and six months ended June 30, 2009.

26 Aug 2009

Genvec to use $2.5 million grant from NIAID for the development of novel cell lines

GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Phase 2 Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of GenVec's vector production technology.

25 Aug 2009

Orphan drug status granted to BioCancell's BC-819 drug

Tikcro Technologies today announced that the United States (“US”) Department of Health and Human Services ("HHS") has granted orphan drug status to BioCancell's BC-819 drug, currently in Phase I/IIa clinical trials, for its use in treating ovarian cancer.

24 Aug 2009

Genway Clinical Laboratory offers ELISA-based test that detects tumor markers in blood serum

GenWay Clinical Laboratory, a US-based diagnostic company with CLIA certification, has validated a general tumor marker test in their laboratory and now offers this testing service. This is an ELISA-based assay which simply requires a small blood sample from the patient in order to quantify the amount of the tumor marker in their serum.

24 Aug 2009

National Science Foundation funds CMU for developing revolutionary computational tools

A multidisciplinary team led by Carnegie Mellon University computer scientist Edmund M. Clarke has received a five-year, $10 million grant from the National Science Foundation's Expeditions in Computing program to create revolutionary computational tools that will advance science on a broad array of fronts, from discovering new cancer treatments to designing safer aircraft.

20 Aug 2009

ImmunoCellular Therapeutics to participate in the Southern California Investor Conference

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it will participate in the Southern California Investor Conference being held in Newport Beach, CA, on Tuesday August 18, 2009.

19 Aug 2009

Prion found to be a biomarker for pancreatic cancer

Mad cow disease is caused by the accumulation of an abnormal protein, the prion, in the brain of an affected patient. Outside of the brain, very little is known about prions.

18 Aug 2009

Easy-to-swallow drug restores autoimmune function in diabetics

Found in 30% of all human cancer tumors, the Ras protein literally "drives cells crazy," says Prof. Yoel Kloog, the dean of the Faculty of Life Sciences at Tel Aviv University. Prof. Kloog was the first in the world to develop an effective anti-Ras drug against pancreatic cancer, currently in clinical trials. Now, new research published in the June issue of the European Journal of Pharmacology shows that the drug might be able to slow the progression of diabetes as well.

11 Aug 2009

Two significant advances in treating lung cancer

Dr. Glen Weiss of the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare this week announced two significant advances in treating lung cancer at an international cancer research conference.

7 Aug 2009

Heavy drinkers have much higher risk of developing cancer

Heavy drinkers of beer and spirits face a much higher risk of developing cancer than the population at large, says a group of Montreal epidemiologists and cancer researchers.

4 Aug 2009

New blood tests may detect pancreatic cancer more effectively

A new diagnostic tool developed by Van Andel Research Institute (VARI) scientists has shown promising results when used with patients of pancreatic cancer, one of the deadliest forms of cancer due to the difficulty of diagnosing it in its early stages. The method, which studies carbohydrate structures in the bloodstream, could lead to the development of blood tests that can detect cancer more effectively.

3 Aug 2009

Heavy consumption of beer and spirits to 6 different cancers

Heavy drinkers of beer and spirits face a much higher risk of developing cancer than the population at large, says a group of Montreal epidemiologists and cancer researchers. Their findings show that people in the highest consumption category increased their risk of developing oesophageal cancer sevenfold, colon cancer by 80% and even lung cancer by 50%.

3 Aug 2009

Pancreatic Cancer News and Research

Further Reading

Biosante and Cell Genesys to merge after stockholders' approval

Biosante Pharmaceuticals and Cell Genesys to hold stockholders meeting for merger approval

Phase I clinical trial data of GDC-0449 published in the New England Journal Of Medicine

Study reports a potential new investigational therapy for skin cancer

New therapy for advanced and metastatic basal cell skin cancer

Statistics reveals that blacks experience higher rates of pancreatic cancer deaths than whites

Leading experts in health and health care reform to take part in symposium

Genvec to sell 8,000,000 shares to develop its TNFerade clinical program

Tikcro Technologies announces financial results for the second-quarter ended June 30, 2009

Genvec to use $2.5 million grant from NIAID for the development of novel cell lines

Orphan drug status granted to BioCancell's BC-819 drug

Genway Clinical Laboratory offers ELISA-based test that detects tumor markers in blood serum

National Science Foundation funds CMU for developing revolutionary computational tools

ImmunoCellular Therapeutics to participate in the Southern California Investor Conference

Prion found to be a biomarker for pancreatic cancer

Easy-to-swallow drug restores autoimmune function in diabetics

Two significant advances in treating lung cancer

Heavy drinkers have much higher risk of developing cancer

New blood tests may detect pancreatic cancer more effectively

Heavy consumption of beer and spirits to 6 different cancers

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News